

18 **ABSTRACT**

19 Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been
20 associated with concerning changes of the virus, including resistance to neutralizing antibodies
21 and increased transmissibility. While the concerning variants are fast spreading in various
22 geographical areas, identification and monitoring of these variants is lagging far behind, due in
23 large part to the slow speed and insufficient capacity of viral sequencing. In response to the
24 unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular
25 assay for rapid and simultaneous identification of E484K and N501Y mutations from
26 nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this
27 tool, we screened a total of 435 clinical NS samples collected from COVID patients at 8
28 hospitals within the Hackensack Meridian Health network in New Jersey. While B.1.351 and P.1
29 variants were absent from the current study, our data revealed a dramatic increase in the
30 frequency of E484K over time, underscoring the need for continuous epidemiological
31 monitoring.

32

33 **Key words:** SARS-CoV-2, variants, E484K, N501Y, screening

34 The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-
35 CoV-2) has plagued human society causing immeasurable losses in an unprecedented way. In
36 the circumstances, many monoclonal and polyclonal antibodies have been approved for clinical
37 use and several vaccines have been licensed with two mRNA vaccines and one viral vectored
38 vaccine being rolled out for population vaccination in various countries and geographical areas.
39 Opposed to these encouraging progresses and facts, this virus has quickly adapted to various
40 pressures from antiviral therapy and host immunity and evolved independently into several
41 SARS-CoV-2 variants of concern (VOC). These variants, including B.1.1.7 (a.k.a. 501Y.V1),
42 B.1.351(a.k.a. 501Y.V2), and P.1(a.k.a. 501Y.V3) variants, are concerning because they either
43 resist neutralizing antibody and possibly reduce vaccine efficacy or show increased
44 transmissibility, via making some key mutations in the spike protein [1, 2, 3, 4, 5]. Studies have
45 shown that currently observed resistance to neutralizing antibody is largely associated with the
46 E484K mutation [1, 2, 5, 6, 7]. Previously, E484K was only harbored by B.1.351 and P1
47 variants. The most recent report found that the E484K has been successfully incorporated into
48 some isolates of the B.1.1.7 variant [8]. Moreover, the new variant of interest discovered in New
49 York (B.1.526) also carries the E484K mutation, and alarmingly, fast-spreading over the past
50 two months [9, 10]. Another key spike mutation, N501Y, present in all three VOCs is considered
51 to enhance the binding between spike and the ACE2 receptor in human cells, thus contributing
52 to increased transmissibility and possibly virulence as well [11, 12, 13]. As we continue to
53 understand the impact of these variants on the mode of the ongoing pandemic, efficient and
54 continuous monitoring of these variants is critical to implementation of fast and effective
55 countermeasures to eventually defeat this devastating disease. The closer this genotyping can
56 happen to the testing, the quicker the data can be used and actioned. To this end, we
57 developed a novel molecular diagnostic assay capable of identifying the signature mutations
58 within 2.5 h from sample preparation to report, and used this tool to screen clinical

59 nasopharyngeal swabs (NS) collected from COVID patients at Hackensack Meridian Health
60 (HMH) network hospitals from late December 2020 to February 2021.

61
62 This novel genotyping is based on the thermal dynamic difference of molecular beacon (MB)
63 binding with perfectly complementary target or mismatch target. To generate single-stranded
64 target DNA for the MB probe, an asymmetric reverse transcription (RT)-PCR assay was
65 developed to amplify the mutation hotspot region covering both 484 and 501 codons of the S
66 gene (**supplemental material**). Upon completion of thermal cycling, a melting curve analysis is
67 performed to characterize dissociation between the single-stranded DNA product and two
68 differentially labeled MB probes, to enable simultaneous genotyping at both loci. Owing to the
69 probe design, the wildtype (WT) template is expected to generate a higher melting temperature
70 (T_m) than that of the mutated genotype at corresponding locus. As shown on **Fig. 1**, E484 WT
71 is featured for a T_m at $54.85^\circ\text{C} \pm 0.19^\circ\text{C}$, $\sim 5^\circ\text{C}$ higher than the T_m of E484K ($49.81^\circ\text{C} \pm$
72 0.07°C). Similarly, the signature T_m for N501 WT was $59.97^\circ\text{C} \pm 0.09^\circ\text{C}$, higher than $54.78^\circ\text{C} \pm$
73 0.12°C for N501Y. In a blinded fashion, this test correctly genotyped RNA samples extracted
74 from 6 different reference viral strains, including one WT (SARS-CoV-2 USA WA1/2020), two
75 B.1.1.7 variants (SARS-CoV-2 hCoV-19/USA/CA_CDC_5574/2020 and SARS-CoV-2 hCoV-
76 19/England/204820464/2020), and two B.1.351 variants (SARS-CoV-2 hCoV-19/South
77 Africa/KRISP-EC-K005321/2020 and SARS-CoV-2 hCoV-19/South Africa/KRISP-
78 K005325/2020) purchased from BEI resources, and one E484K variant isolate recently obtained
79 from our network hospital. The analytical sensitivity of the assay was evaluated against 10-fold
80 serial dilutions of RNA prepared from each of the reference viral strain. The assay can reliably
81 identify as low as 200 copies of 484WT, 200 copies of E484K, 20 copies of 501WT, and 200
82 copies of N501Y per reaction, respectively.

83

84 Using this tool, we next accessed to SARS-CoV-2 positive NS specimens through the HMH
85 institutional Biorepository under an HMH-IRB approved protocol Pro2018-1022, to screen the
86 signature mutations. This study also accessed de-identified data for time and location of sample
87 collection through the HMH-IRB approved protocol, Pro2020-0342. A total of 435 samples
88 received in February 2021 from 8 HMH hospitals with a cycle of threshold (Ct) value <37 in
89 SARS-CoV-2 N2 RT-PCR test [14] were subjected to the spike mutation screening.

90

91 To speed up the screening procedure, we adopted an extraction-free sample process method
92 by heat inactivating a 50 μ l aliquot of swab specimen in the presence of proteinase K at 95°C
93 for 5 min [15], prior to genotyping test. As a result, 365 and 376 samples yielded identifiable
94 signals for 484 and 501 sites, respectively. The proportion of E484K was 8.8% (32/365), and it
95 was 8.0% (30/376) for N501Y. Of note, the presence of E484K and N501Y in the tested
96 samples was completely independent. Co-harboring of both mutations was not observed in our
97 screening. In addition, we discovered a new genotype at the 501-probe binding site from 11
98 samples (11/376, 2.9%), which thereafter was confirmed to be a N501T (AAT>ACT) mutation in
99 subsequent sequencing. The melting profile of N501T is markedly different from that of WT and
100 N501Y, with a signature T_m of 56.41°C \pm 0.15°C. A sharp increase was noticed in both E484K
101 and N501Y prevalence in February compared to earlier months. E484K cases account for
102 12.0% (29/242) of all samples in February. In contrast, it was not detected in samples of
103 December (n=28), and only 3.2% (3/95) of samples of January were E484K positive. The
104 N501Y followed the same trend, with 11.2% (28/251) prevalence in February, and 1.0% (1/98)
105 and 3.7% (1/27) in January and December, respectively. Further analysis by sample collection
106 source found that E484K scattered in various hospitals, whereas N501Y seemed to be highly
107 concentrated in one hospital area (20/107 vs. 10/249, $P=0.001$), indicating a possible small
108 outbreak which warrants further investigation.

109

110 We next performed whole genome sequencing (WGS) with a panel of 74 samples representing
111 different genotypes flagged by this screening tool, including 24 E484K, 25 N501Y, 5 N501T, and
112 20 WT at 484 and 501 loci. Indeed, WGS results are 100% consistent with our genotyping
113 determination. Genomic analysis (**Fig. S**) showed that the majority of the E484K cases (n=19)
114 fell within the B.1.526 lineage, a recent clone emerged from New York, and the rest belong to
115 clade 20C B.1 lineage (n=2), and clade 20B under R.1 (n=2) and B.1.1.309 lineage (n=1),
116 respectively. All N501Y cases except one are members of B.1.1.7 lineage.

117
118 Currently, WGS is being used as the main tool for epidemiological monitoring of SARS-CoV-2
119 variants. However, the relatively long turn-around-time for WGS and the demand on
120 bioinformatic expertise for data analysis makes identification of concerning variants lagged far
121 behind laboratory COVID diagnosis. Clearly, there is an unmet need for faster and simpler
122 screening tool that can be used in a high-throughput fashion to increase the capacity of SARS-
123 CoV-2 variant detection in real-time. Herein, we demonstrate that a novel and easy molecular
124 diagnostic assay can be used as a convenient tool for large scale of SARS-CoV-2 variant
125 screening, thus, to enable highly efficient epidemiological monitoring. Not only the assay is
126 proved to be highly accurate in our clinical screening, notably, it is also sensitive to new
127 mutations within the probe binding site. This has been well exemplified by our discovery of the
128 N501T mutation from the clinical specimens. To our knowledge, this is the first report of using
129 novel screening tool to identify key mutation harboring SARS-CoV-2 variants in NJ hospitals.
130 B.1.351 and P.1 variants were absent from the current study, however our data revealed a
131 dramatic increase in the frequency of E484K over time, underscoring the need for continuous
132 epidemiological monitoring.

133
134 A couple of limitations of this study need to be noted. Firstly, this novel screening assay is
135 slightly less sensitive than the widely used RT-PCR COVID diagnostic assay. Therefore,

136 samples with very low viral load (eg: N2 Ct >35) may not yield identifiable signal in this
137 genotyping test. Efforts towards improving the sensitivity of the test is ongoing. Secondly, the
138 current assay only aims at picking up mutations at 484 and 501 loci. It is our intention to keep
139 expanding and updating this test by adding new mutations associated with important phenotypic
140 change, to better respond to the fast-evolving situation.

141

142 **ACKNOWLEDGMENTS**

143 This work was supported by the COVID Emergency Research Fund #61315, Hackensack
144 University Medical center; by funds provided to the CDI by Activision Publishing Inc, Suez North
145 America, and by *NJ Stands Up to COVID*. The funders of this study had no role in the study
146 design, data collection, data analysis, data interpretation, or writing of the report. All authors
147 declare no conflict of interest in this work. Whole genome sequencing was performed at the
148 New York Genome Center (NYGC) as part of the COVID-19 Genomic Research Network
149 (CGRN) with funds generously provided by NYGC donors.

150 We thank Steven Park, Nathaly Cabrera, and Timothy Mikulski for technical support of viral
151 culture and RNA extraction.

152


153 **REFERENCES**

- 154 1. Diamond M, Chen R, Xie X, et al. SARS-CoV-2 variants show resistance to
155 neutralization by many monoclonal and serum-derived polyclonal antibodies. *Research*
156 *square*. 2021 Feb 10. doi: 10.21203/rs.3.rs-228079/v1. PubMed PMID: 33594356;
157 PubMed Central PMCID: PMC7885928. eng.
- 158 2. Gröhs Ferrareze PA, Franceschi VB, de Menezes Mayer A, et al. E484K as an
159 innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike
160 mutation in SARS-CoV-2 lineages from Brazil. 2021:2021.01.27.426895. doi:
161 10.1101/2021.01.27.426895 %J bioRxiv.


- 162 3. Kupferschmidt K. Fast-spreading U.K. virus variant raises alarms. *Science* (New York,
163 NY). 2021 Jan 1;371(6524):9-10. doi: 10.1126/science.371.6524.9. PubMed PMID:
164 33384355; eng.
- 165 4. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization
166 by South African COVID-19 donor plasma. *Nature medicine*. 2021 2021/03/02. doi:
167 10.1038/s41591-021-01285-x.
- 168 5. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351
169 and B.1.1.7. *Nature*. 2021 Mar 8. doi: 10.1038/s41586-021-03398-2. PubMed PMID:
170 33684923; eng.
- 171 6. Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly
172 neutralizing COVID-19 convalescent plasma. *bioRxiv : the preprint server for biology*.
173 2020 Dec 28. doi: 10.1101/2020.12.28.424451. PubMed PMID: 33398278; PubMed
174 Central PMCID: PMCPMC7781313 Emanuele Andreano, Ida Paciello, Elisa Pantano,
175 Noemi Manganaro and Rino Rappuoli are listed as inventors of full-length human
176 monoclonal antibodies described in Italian patent applications n. 102020000015754 filed
177 on June 30(th) 2020 and 102020000018955 filed on August 3(rd) 2020. eng.
- 178 7. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-
179 CoV-2 spike protein variants. *eLife*. 2020 Oct 28;9. doi: 10.7554/eLife.61312. PubMed
180 PMID: 33112236; PubMed Central PMCID: PMCPMC7723407. eng.
- 181 8. Wise J. Covid-19: The E484K mutation and the risks it poses. *BMJ* (Clinical research
182 ed). 2021 Feb 5;372:n359. doi: 10.1136/bmj.n359. PubMed PMID: 33547053; eng.
- 183 9. Annavajhala MK, Mohri H, Zucker JE, et al. A Novel SARS-CoV-2 Variant of Concern,
184 B.1.526, Identified in New York. 2021:2021.02.23.21252259. doi:
185 10.1101/2021.02.23.21252259 %J medRxiv.

- 186 10. Lasek-Nesselquist E, Lapierre P, Schneider E, et al. The localized rise of a B.1.526
187 SARS-CoV-2 variant containing an E484K mutation in New York State.
188 2021:2021.02.26.21251868. doi: 10.1101/2021.02.26.21251868 %J medRxiv.
- 189 11. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7
190 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morbidity and
191 mortality weekly report. 2021 Jan 22;70(3):95-99. doi: 10.15585/mmwr.mm7003e2.
192 PubMed PMID: 33476315; PubMed Central PMCID: PMCPMC7821772 Journal Editors
193 form for disclosure of potential conflicts of interest. No potential conflicts of interest were
194 disclosed. eng.
- 195 12. Iacobucci G. Covid-19: New UK variant may be linked to increased death rate, early data
196 indicate. BMJ (Clinical research ed). 2021 Jan 26;372:n230. doi: 10.1136/bmj.n230.
197 PubMed PMID: 33500262; eng.
- 198 13. Washington NL, Gangavarapu K, Zeller M, et al. Genomic epidemiology identifies
199 emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
200 medRxiv : the preprint server for health sciences. 2021 Feb 7. doi:
201 10.1101/2021.02.06.21251159. PubMed PMID: 33564780; PubMed Central PMCID:
202 PMCPMC7872373. eng.
- 203 14. Zhao Y, Cunningham MH, Mediavilla JR, et al. Diagnosis, clinical characteristics, and
204 outcomes of COVID-19 patients from a large healthcare system in northern New Jersey.
205 Scientific reports. 2021 Feb 23;11(1):4389. doi: 10.1038/s41598-021-83959-7. PubMed
206 PMID: 33623090; PubMed Central PMCID: PMCPMC7902820. eng.
- 207 15. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A Simplified and Flexible
208 Platform to Enhance SARS-CoV-2 Testing Capacity. Med (New York, NY). 2020 Dec 26.
209 doi: 10.1016/j.medj.2020.12.010. PubMed PMID: 33521748; PubMed Central PMCID:
210 PMCPMC7836249. eng.

211 **Figure 1. Melting profiles for E484WT and E484K (left panel), and those for N501WT and**
212 **N501Y (right panel). For each genotype, 10-fold serial RNA dilutions containing 2×10^5 to**
213 **200 genome equivalents/reaction were tested. Dashed lines indicate the T_m value of**
214 **corresponding genotype. NTC is the abbreviation for no template control.**



- 484WT 2E5
- 484WT 2E4
- 484WT 2E3
- 484WT 2E2
- E484K 2E5
- E484K 2E4
- E484K 2E3
- E484K 2E2
- NTC



- 501WT 2E5
- 501WT 2E4
- 501WT 2E3
- 501WT 2E2
- N501Y 2E5
- N501Y 2E4
- N501Y 2E3
- N501Y 2E2
- NTC